



May 28, 2026
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

SymBio Secures European Patent for Use of IV BCV for Adenovirus Infection Strengthening Exclusive Patent Rights for IV BCV in Japan, the U.S., and Europe

TOKYO, Japan, May 28, 2026 -- SymBio Pharmaceuticals Limited (“SymBio” or the “Company”) today announced that it has obtained a European patent for the use of IV BCV (intravenous brincidofovir) for the treatment of adenovirus infection following hematopoietic stem cell transplantation.

With this patent now granted in Europe, and in addition to the rights already secured in Japan and the United States, SymBio has established patent exclusivity for adenovirus infection across all three major markets—Japan, the U.S., and Europe. This further strengthens the foundation of the intellectual property portfolio for brincidofovir in preparation for global expansion of the Company’s business going forward.

Regarding the European market, IV BCV has already been granted Orphan Drug Designation (ODD) for this adenovirus infection, and approval under the Pediatric Investigation Plan (PIP) has provided an additional two-year extension of the regulatory exclusivity period. By combining this patent with the regulatory incentives, SymBio has established a robust market exclusivity framework to maximize the business value of IV BCV over the medium to long term.

Statement from Fuminori Yoshida, President and CEO: “The granting of this patent in Europe marks an extremely important milestone in our global strategy. We will continue to maximize the business value of IV BCV and accelerate our development activities to bring this innovative therapeutic option to patients as quickly as possible.”

A Phase III clinical trial is currently ongoing for adenovirus infection following hematopoietic stem cell transplantation, and patient enrollment is under way in Europe and the United States. The Company achieved First Patient In (FPI) in March. Please refer to the Company’s press release dated March 17, 2026 ([First Patient In \(FPI\) Achieved in Phase III Clinical Trial of IV BCV for the Treatment of Adenovirus Infection After HSCT](#)).



This matter is not expected to have a material impact on the Company's consolidated financial results for the fiscal year ending December 2026.

[Contact]

Investor Relations

Tel: +81 (0)3 5472 1125

Notes

Overview of this Use Patent

[Patent No.] Patent No. 4,506,008

[Patent Holder] SymBio Pharmaceuticals Limited

[Expiration Date] April 29, 2044

[Purpose] Regimen and dosage of IV BCV for the treatment of adenovirus infection or diseases associated with adenovirus infection

Overview of Use Patent for IV BCV in Adenovirus Indication

[Patent Holder] SymBio Pharmaceuticals Limited

[Term of Validity] Japan : August 7, 2043 (Patent No. 7,417,339)

U.S. : May 6, 2044 (Patent No. 12,544,392)

[Scope] Clinical regimen (dosing and administration) of IV BCV for the treatment of adenovirus infection

Patent No. 4,506,008 covers the clinically relevant regimen and dosage of IV BCV for adenovirus infection following hematopoietic stem cell transplantation. It is intended to protect the regimen and dosage and other appropriate-use information expected to be described in the package insert following marketing approval of the new drug, and, in addition to the formulation patents, it secures additional exclusivity in Japan, the U.S., and Europe based on real-world clinical use by disease area.

About SymBio : BCV Business Strategy Based on Three Therapeutic Pillars

Since obtaining the global license for BCV in September 2019, SymBio has advanced collaborative research with world-class institutions to unlock IV BCV's potential across three strategic therapeutic areas where the Company is currently focusing its development resources:



(1) viral infections following hematopoietic stem cell transplantation; (2) hematologic and solid tumors; and (3) neurodegenerative diseases. By concentrating management resources on these therapeutic areas and actively promoting global business expansion, SymBio aims to maximize the business value of BCV.